Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.50 |
| ▸ | CA1 | P00915 | 12/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202947 | 0.81 | CA2 (0.70) | CA2CA1CA9CA6CA5A | |
| SCHEMBL28044927 | 0.78 | MYC (0.40) | CA2CA1CA9CA12 | |
| SCHEMBL45019 | 0.78 | CA2 (0.55) | CA2CA1CA9CA6CA5A | |
| SCHEMBL10749655 | 0.78 | CA2 (0.67) | CA2CA1CA9CA6CA5A | |
| SCHEMBL10750176 | 0.78 | CA2 (0.67) | CA2CA1CA9CA6CA5A | |
| SCHEMBL10750170 | 0.78 | CA2 (0.67) | CA2CA1CA9CA6CA5A | |
| SCHEMBL8779451 | 0.76 | KAT6A (0.51) | — | |
| SCHEMBL13850926 | 0.75 | CA2 (0.47) | CA2CA1CA9CA6CA5A | |
| SCHEMBL20943708 | 0.75 | HTR6 (0.52) | CA2CA1CA12CA7 | |
| SCHEMBL29488962 | 0.75 | HTR6 (0.52) | CA2CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096782-A1 | FLUORINATED CANNABINOID COMPOSITIONS AND METHODS THEREOF | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2025-05-08 | — | — | WO | claimed |
| WO-2022269257-A1 | SPIRO-(FLUORENE-9,9'-(THIO)XANTHENES) | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2022-12-29 | — | — | WO | claimed |
| EP-3426654-B1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | HARVARD COLLEGE (US) | 2021-10-20 | — | — | EP | claimed |
| CN-108610388-B | Preparation method of macrolide | 浙江京新药业股份有限公司 | 2020-11-06 | — | — | CN | claimed |
| US-10597366-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-03-24 | — | — | US | claimed |
| US-20190119214-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-04-25 | — | — | US | claimed |
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | EMORY UNIVERSITY | 2019-03-14 | — | — | US | claimed |
| EP-3426654-A1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | President and Fellows of Harvard College (US) | 2019-01-16 | — | — | EP | claimed |
| WO-2018134343-A1 | SYNTHESIS OF PHOSPHORAMIDATES | SANDOZ AG (CH) | 2018-07-26 | — | — | WO | claimed |
| US-20170283960-A1 | METHOD OF DISCOVERING FLUORO-CONTAINING COMPOUNDS | SHANXI CHEMICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2017-10-05 | — | — | US | claimed |
| WO-2017156265-A1 | DIRECT PALLADIUM-CATALYZED AROMATIC FLUORINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-14 | — | — | WO | claimed |
| WO-2016106161-A1 | METHOD OF DISCOVERING FLUORO-CONTAINING COMPOUNDS | SHANXI CHEMICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2016-06-30 | — | — | WO | claimed |
| EP-0708087-B1 | Method for making a substituted benzene compound | ROHM & HAAS (US) | 1999-07-28 | — | — | EP | claimed |
| US-5670691-A | REACTION OF 2-SUBSTITUTED BENZENESULFONATE WITH LITHIUM COMPOUND THEN REACTION WITH ELECTROPHILE TO FORM 2,6-DISUBSTITUTED BENZENESULFONATE | ROHM AND HAAS COMPANY (US) | 1997-09-23 | — | — | US | claimed |
| EP-0708087-A1 | Method for making a substituted benzene compound | ROHM AND HAAS COMPANY (US) | 1996-04-24 | — | — | EP | claimed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| US-5254732-A | N-fluorosulfonimides and their application as fluorinating agents | ALLIED-SIGNAL INC. (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0554025-A2 | Fluorinated cyclobutyl purines and pyrimidines | E.R. SQUIBB & SONS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| EP-0526849-A1 | Novel substituted N-Fluoropyridiniumsulfonate, intermediates therefor and preparation processes thereof | DAIKIN INDUSTRIES, LTD. (JP) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077797-A1 | PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES | DERA, DPYD, DUS2 | CA2 3122/4885CA1 2993/4885CA9 2497/4885 |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | CA2 2256/4885CA1 2823/4885CA9 1702/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | CA2 1052/4885CA1 4250/4885CA9 2969/4885 |
| US-20190119214-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | CA2 1902/4885CA1 2771/4885CA9 647/4885 |
| US-10597366-B2 | Aryl ethers and uses thereof | HIF1AN, EGLN2, VHL | CA2 1902/4885CA1 2771/4885CA9 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.